In Vivo - Strategic Analysis For Medtech And Pharma Leaders since 1981
Exploring Latin America In The COVID-19 Era
Unique industry partnerships and new regulatory flexibility in Latin America may help to improve access to medicines, even as COVID-19 wreaks havoc in the region’s largest pharmaceutical market. Can biopharma’s bespoke solutions to market access barriers coalesce into a strategy capable of overcoming political, economic and COVID-19 related risks?
India’s Bulk Drugs Incentive Scheme Finds First Takers
As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products – they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen..
Fewer Acquisitions And Alliances In 2023, But Valuations Increased
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
